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Abstract
Purpose: RayStation treatment planning system employs pencil beam (PB) and
Monte Carlo (MC) algorithms for proton dose calculations. The purpose of this study
is to evaluate the radiobiological and dosimetric impact of RayStation PB and MC
algorithms on the intensity‐modulated proton therapy (IMPT) breast plans.
Methods: The current study included ten breast cancer patients, and each patient
was treated with 1–2 proton beams to the whole breast/chestwall (CW) and regional
lymph nodes in 28 fractions for a total dose of 50.4 Gy relative biological effective-
ness (RBE). A total clinical target volume (CTV_Total) was generated by combining
individual CTVs: AxI, AxII, AxIII, CW, IMN, and SCVN. All beams in the study were
treated with a range shifter (7.5 cm water equivalent thickness). For each patient,
three sets of plans were generated: (a) PB optimization followed by PB dose calcula-
tion (PB‐PB), (b) PB optimization followed by MC dose calculation (PB‐MC), and (c)
MC optimization followed by MC dose calculation (MC‐MC). For a given patient,
each plan was robustly optimized on the CTVs with same parameters and objectives.
Treatment plans were evaluated using dosimetric and radiobiological indices (equiva-
lent uniform dose (EUD), tumor control probability (TCP), and normal tissue compli-
cation probability (NTCP)).
Results: The results are averaged over ten breast cancer patients. In comparison to
PB‐PB plans, PB‐MC plans showed a reduction in CTV target dose by 5.3% for
D99% and 4.1% for D95%, as well as a reduction in TCP by 1.5–2.1%. Similarly, PB
overestimated the EUD of target volumes by 1.8─3.2 Gy(RBE). In contrast, MC‐MC
plans achieved similar dosimetric and radiobiological (EUD and TCP) results as the
ones in PB‐PB plans. A selection of one dose calculation algorithm over another did
not produce any noticeable differences in the NTCP of the heart, lung, and skin.
Conclusion: If MC is more accurate than PB as reported in the literature, dosimetric
and radiobiological results from the current study suggest that PB overestimates the
target dose, EUD, and TCP for IMPT breast cancer treatment. The overestimation of
dosimetric and radiobiological results of the target volume by PB needs to be fur-
ther interpreted in terms of clinical outcome.
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1 | INTRODUCTION
Intensity‐modulated proton therapy (IMPT) is used for the treatment
of breast cancer at many proton centers across the world. Litera-
ture1,2 has shown that proton therapy for breast cancer could poten-
tially reduce normal tissue complication probability (NTCP) by
reducing side effects such as cardiac and pulmonary toxicities. It is
paramount that the reduction of NTCP must be accompanied by an
increase in tumor control probability (TCP) to prevent tumor recur-
rence. Both the TCP and NTCP are calculated based on the
absorbed dose in disease sites and normal tissues, respectively.
Hence, the accuracy of proton dose calculation algorithm is critical
in estimating the absorbed dose in tumors and organs at risk (OARs).
RayStation (version 6.1.1.2; RaySearch Laboratories, Stockholm,
Sweden) employs analytical pencil beam (PB) and Monte Carlo (MC)
algorithms for proton dose calculations. Several studies3–8 have high-
lighted the limitation of PB algorithm within RayStation for dose cal-
culation, especially in the presence of range shifter and
inhomogeneities. For instance, Saini et al.3 found that MC is superior
to PB when a range shifter is employed with oblique beams, large
air gaps, and/or heterogeneous media. Taylor et al.4 demonstrated
that MC calculations are more accurate than PB calculations when
compared to physical measurements. Shirey et al.6 showed better
accuracy of MC compared to PB when treatment involves the range
shifter and superficial lesions.
Although superior dose prediction accuracy of MC over PB has
been well established,3–8 literature investigating the impact of RayS-
tation PB and MC on IMPT breast cancer treatment is scarce. The
investigation of proton dose calculation algorithms for breast treat-
ment is particularly important due to the presence of a tumor at a
shallower depth and range shifter in the proton beam path. The
addition of range shifter at the end of the nozzle exit reduces the
beam energy. This is necessary to achieve a full dose modulation of
the tumor volume, but the range shifter creates an air gap between
its downstream and patient surface, thus increasing in‐air spot size.9
Tommasino et al.7 included five breast cancer patients and the
treatment plans were optimized with PB and recalculated with PB
and MC. Additionally, Tommasino et al.7 performed the phantom
measurements to demonstrate better accuracy using MC than using
PB. Liang et al.8 did a more comprehensive dosimetric study by
including 20 breast cancer patients. In their study,8 the authors used
both PB and MC for plan optimization as well as dose calculations,
whereas MC for plan optimization was not addressed by Tommasino
et al.7 It is worth noting that both studies evaluated PB and MC on
IMPT breast plans using dosimetric indices. However, at the time of
writing this paper, the radiobiological impact of RayStation PB and
MC on IMPT breast plans is yet to be investigated.
The goal of this study is twofold. First, we investigated the radio-
biological impact of RayStation PB and MC algorithms on IMPT breast
plans. Specifically, treatment plans are evaluated in terms of equiva-
lent uniform dose (EUD), TCP, and NTCP. Our study included plans
optimized using PB and MC as well as dose calculated using PB and
MC. Second, since there is only one dosimetric study8 from a single
institution investigating the use of RayStation MC for plan optimiza-
tion of IMPT breast cancer planning, independent research from
another institution on this topic is essential. Our study aims to supple-
ment the work of Liang et al.8 by comparing the dosimetric results of
PB and MC for IMPT breast cancer treatment. Additionally, for each
case, we have presented a more comprehensive analysis of plan
robustness and computational time— results of these two parameters
were not provided in detail in a previous publication.8
2 | MATERIALS AND METHODS
2.A | Patients, CT simulation, and contouring
The current study consisted of ten female left breast cancer patients
who have been treated using IMPT at our center between 11/2017
and 01/2019. All ten patients received treatment to the chest wall
(CW) or whole breast. For all ten patients, the treatment also
included regional lymph nodes. Patients were simulated on Siemens
computed tomography (CT) Scanner (Siemens Healthcare, Forcheim,
Germany) in head‐first supine treatment position with arms above
their heads based on our institutional protocol. This includes a vac‐
lok and wing board for immobilization devices and a free breathing
CT scan with a slice thickness of 2 mm.
For contouring of target volumes and OARs, CT images were
transferred either to RayStation or Velocity (Varian Medical Systems,
Palo Alto, CA, USA). A total clinical target volume (CTV_Total) was
generated by combining individual CTV structures: breast or CW,
axillary level I–III nodes (AxI‐III), internal mammary nodes (IMN), and
supraclavicular nodes (SCVN). The OARs included the heart, left
lung, right lung, esophagus, left anterior descending artery (LAD),
and skin (either 3 mm (CW) or 5 mm (whole breast) inward from the
body surface).
2.B | Dose prescription and treatment planning
All ten patients were treated for a total dose of 50.4 Gy relative bio-
logical effectiveness (RBE) in 28 fractions on a ProteusPLUS PBS
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proton therapy system10 (Ion Beam Applications, Louvain‐la‐Neuve,
Belgium). Treatment plans were generated in RayStation (v6.1.1.2)
using 1–2 beams, and each beam included the range shifter of
7.5 cm water equivalent thickness made up of lucite. A 5 mm setup
uncertainty on CTV was used for the robust optimization for a total
of seven scenarios. All treatment plans were robustly optimized with
the goal of 95% of CTV receiving at least 95% of the prescription
dose while minimizing dose to the OARs. All plans were computed
with a dose calculation grid size of 3 mm. For each case, three plans
were generated using identical beam angles, air gap, optimization
structures, optimization constraints, and optimization settings. A
sampling history of 10,000 ions/spot was used for MC optimization,
and a statistical uncertainty of 0.5% was used for MC dose calcula-
tion.
1. PB‐PB Plan: The plan was optimized using PB followed by dose
calculation using PB.
2. PB‐MC Plan: The plan was optimized using PB followed by dose
calculation using MC.
3. MC‐MC Plan: The plan was optimized using MC followed by
dose calculation using MC.
2.C | Dosimetric analysis
The CTV_Total was evaluated for the mean dose (Dmean), the dose
received by 99% of the volume (D99%), 95% of the volume (D95%),
and 2% of the volume (D2%). The Dmean was calculated for the left
anterior descending artery (LAD), heart, and esophagus, whereas the
dose received by 0.03 cc (Dmax) was calculated for the skin. The ipsi-
lateral lung (i.e., left lung) was evaluated for the relative volume that
received 20 and 5 Gy(RBE) (V20 and V5, respectively), whereas the
contralateral lung (i.e., right lung) was evaluated for the V5.
2.D | EUD Analysis
Equivalent uniform dose evaluation was performed using the cumu-
lative dose volume histograms (DVHs) of the proton treatment plans
(PB‐PB, PB‐MC, and MC‐MC). EUD is based on the Niemierko’s phe-
nomenological model.11
The EUD11,12 is defined as.
EUD ¼ ∑i¼1 viEQDai
  1
a (1)
EQD ¼ D
α
β þ Dnf
 
α
β þ 2
  (2)
In eq. (1), a is a unit less model parameter that is specific to the
normal structure or tumor of interest, and vi is unit less and represents
the ith partial volume receiving dose Di in Gy.
11,12 Since the relative
volume of the whole structure of interest corresponds to 1, the sum of
all partial volumes vi will equal 1
11,12 The EQD is the biologically equiv-
alent physical dose of 2 Gy. In eq (2), nf and df = D/nf are the number
of fractions and dose per fraction size of the treatment course,
respectively. The α/β is the tissue‐specific linear‐quadratic (LQ) param-
eter of the organ being exposed. The EUD calculations in this study
are based on the parameters listed in Table 1.14–16
2.E | TCP Analysis
The Poisson linear quadratic (PoissonLQ) radiobiological model13
employed within RayStation was used to estimate the TCP of
CTV_Total, CTV_breast, CTV_AxI, CTV_AxII, CTV_AxIII, CTV_IMN,
and CTV_SCVN. The TCP‐PossionLQ model is defined as13:
TCPðDÞ ¼
YM
i¼1
exp N0 exp ∑nk¼1 αdk;i  βd2k;i
n o  h i vi
Vref
TCPðDÞ ¼
YM
i¼1
exp  exp eγ  EQD2;i
D50
eγ  lnðlnð2ÞÞð Þ
  	  vi
Vref
(3)
where, M, total number of voxels; D, total dose; Dk,i, dose to the k
th
fraction to voxel i; n, total number of fractions; N0, initial number of
cells; α, parameter of LQ model; β, parameter of LQ model; vi/Vref,
relative volume of voxel i compared to the reference volume; D50,
dose giving a 50% response probability; γ, maximum normalized gra-
dient of the dose response curve; EQD2,i, equivalent dose in voxel i
given in 2 Gy‐fractions.
The values of radiobiological parameters14–16 used for TCP calcu-
lations are provided in Table 1.
2.F | NTCP Analysis
The Lyman‐Kutcher‐Burman (LKB) model employed within RaySta-
tion13 was used to calculate the NTCP of the heart, lung (ipsilateral),
and skin. The LKB model is defined as13:
NTCPðDÞ ¼ 1ffiffiffiffi
2π
p
Rt
1
e
x2
2 dx
t ¼ DeffD50m:D50
(4)
Deff ¼ ∑Mi¼1
vi
Vref
EQD1=ni
 	n
(5)
where, D, total dose; D50, dose giving a 50% response probability; m,
slope of the response curve; M, total number of voxels; n, parameter
reflecting the biological properties of the organ specifying volume
dependence; vi/Vref, relative volume of voxel i compared to the refer-
ence volume; EQDi, equivalent dose in voxel i given in 2 Gy‐frac-
tions.
TAB L E 1 Radiobiological parameters of EUD & TCP calculations for
the breast cancer plans.
Parameter Values Reference
D50 (Gy(RBE)) 30.89
14,15
γ 1.3 14,15
α/β 4 16
a −7.2 14,15
EUD, equivalent uniform dose; TCP, tumor control probability; RBE, rela-
tive biological effectiveness.
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The values of radiobiological parameters17–20 used for NTCP cal-
culations are provided in Table 2.
2.G | Statistical analysis
In order to test the statistical significance of dosimetric and radiobio-
logical results in the current study, the Mann‐Whitney U‐test was
performed. A p value of less than 0.05 was considered to be statisti-
cally significant.
3 | RESULTS
3.A | Dosimetric analysis
Table 3 shows the dosimetric results of nominal PB‐PB, PB‐MC, and
MC‐MC plans. The results are averaged over ten breast cancer
patients. The recalculation of PB plans with MC showed the reduc-
tion in dose to the CTV_Total by the average differences of 5.3%
for D99% (P = 0.001), 4.1% for D95% (P < 0.001), 2.7% for Dmean
(P < 0.001), and 1% for D2% (P = 0.112). The doses to the CTV_Total
in MC‐MC and PB‐PB plans were comparable with no statistical sig-
nificance (P > 0.05). Specifically, on average, the difference in
CTV_Total dose between MC‐MC and PB‐PB plans was less than
0.5% for both D95% and Dmean and 1.4% for D99%. The D2% was sim-
ilar in both MC‐MC and PB‐PB plans. The current study used the
treatment planning goal of CTV_Total D95% = 95% of the prescrip-
tion dose. On average, the CTV_Total D95% was 97.5%, 93.5%, and
97.1% in PB‐PB, PB‐MC, and MC‐MC plans, respectively. For PB‐PB
plans, nine patients had CTV_Total D95%> 95% and one patient had
CTV_Total D95% = 94.8%. MC‐MC plans also exhibited similar results
such that eight patients had CTV_Total D95%> 95% and two patients
had CTV_Total D95% = 94.6% and 94.8%. However, PB‐MC plans
produced inferior results, and there was only one patient with
CTV_Total D95% = 95.1%, and the other nine patients had CTV_Total
D95% results ranging from 91.4% to 94.5%. Figure 1 shows a sample
DVH of CTV_Total in PB‐PB, PB‐MC, and MC‐MC plans of an exam-
ple patient. Figure 2 shows the dose distributions in PB‐PB, PB‐MC,
and MC‐MC plans of an example patient.
The average difference in Dmean to the heart, LAD, and esopha-
gus among different plans (PB‐PB, PB‐MC, and MC‐MC) was less
than 0.5 Gy(RBE) (P > 0.05). The difference in Dmax to the skin
between PB‐MC and PB‐PB plans ranged from −2.3% to 3.7% with
no statistical significance (P = 0.290). The positive difference means
PB‐MC plan has higher Dmax than PB‐PB plan. MC‐MC plans pro-
duced consistently higher Dmax to the skin except in one case. The
difference in Dmax to the skin between MC‐MC and PB‐PB plans
ranged from −0.3% to 1.8% with no statistical significance
(P = 0.406). For the ipsilateral lung, the average V20 among PB‐PB,
PB‐MC, and MC‐MC plans was similar (12.4% vs. 13.9% vs. 22.3%,
respectively). However, in comparison to PB‐PB plans, the difference
in V5 of the ipsilateral lung was slightly higher in PB‐MC plans (2.7%
to 8%; P = 0.082) and MC‐MC plans (0.7% to 13.8%; P = 0.049).
The average V5 of the contralateral lung was similar among PB‐PB
(1.7%), PB‐MC (0.9%), and MC‐MC (1.1%) plans (P > 0.05).
TAB L E 2 Radiobiological parameters of NTCP calculations for the
breast cancer plans.
Structure D50 (Gy(RBE)) m n Reference
Heart 48 0.1 0.35 17,18
Lung (ipsilateral) 37.6 0.35 0.87 18,19
Skin 39 0.14 0.38 20
NTCP, normal tissue complication probability; RBE, relative biological
effectiveness.
TAB L E 3 Dosimetric results in nominal PB‐PB, PB‐MC, and MC‐MC plans of breast cancer. The results are averaged over ten breast cancer
patients.
PB‐PB
Avg. (range)
PB‐MC
Avg. (range) P‐value
MC‐MC
Avg. (range) P‐value
CTV_Total D99% (%) 95.5 (91.6–98.8) 90.4 (87.9–92.6) <0.001 94.1 (92.1–98.1) 0.174
D95% (%) 97.5 (94.8–99.6) 93.5 (91.4–95.1) <0.001 97.1 (94.6–99.3) 0.385
Dmean (%) 100.3 (98.4–101.5) 97.6 (95.3–98.6) <0.001 100 (98.2–101.2) 0.290
D2% (%) 102.6 (100.2–104.3) 101.6 (98.0–104.1) 0.112 102.7 (100.1–104.6) 0.821
Heart Dmean (Gy(RBE)) 0.45 (0.12–1.07) 0.47 (0.1–0.95) 0.762 0.47 (0.11–1.05) 0.970
LAD Dmean (Gy(RBE)) 3.37 (0.43–9.21) 3.10 (0.43–9.06) 0.764 3.64 (0.33–11.17) 0.910
Esophagus Dmean (Gy(RBE)) 6.02 (3.33–17.24) 5.94 (3.63–17.53) 0.705 6.28 (3.71–19.26) 0.850
Skin Dmax (%) 100.2 (94.6–103.1) 101.2 (95.2–105.8) 0.290 100.9 (94.8–104) 0.406
Left lung V20 (%) 12.4 (2.2–22.7) 13.9 (2.6–25.3) 0.406 13.1 (4.9–24.5) 0.597
Left lung V5 (%) 32.8 (21.6–47.5) 37.6 (26.7–53.4) 0.082 36.8 (31.1–51.9) 0.049
Right lung V5 (%) 1.7 (0–9.4) 0.9 (0–4.1) 0.597 1.1 (0–4.2) 0.940
PB‐PB, PB optimization followed by PB dose calculation; PB‐MC, PB optimization followed by MC dose calculation; MC‐MC, MC optimization followed
by MC dose calculation; CTV, clinical target volume; LAD, left anterior descending artery; RBE, relative biological effectiveness.
aP‐value for PB‐MC vs. PB‐PB.
bP‐value for MC‐MC vs. PB‐PB.
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3.B | Robust analysis
The robust analysis was carried out in all three sets of plans (PB‐PB,
PB‐MC, and MC‐mC), and each plan was evaluated for a total of
eight scenarios. Range uncertainty was evaluated for ± 3.5% and
isocenter shift was evaluated for X = ±5 mm, Y = ±5 mm, and
Z = ±5 mm. The acceptable robustness criteria for IMPT breast
treatment was 95% of the CTV_Total is covered by at least 90% of
the prescribed dose (i.e., D95% ≥ 45.36 Gy(RBE)). Figure 3 illustrates
the robust evaluation of the CTV_Total for all ten patients. The
results showed that all three sets of plans (PB‐PB, PB‐MC, and MC‐
MC) achieved the robustness criteria for the IMPT breast treatment
(D95% ≥ 90% of prescription dose) in all ten patients in the current
study.
3.C | EUD analysis
Tables 4 and 5 show the EUD results in PB‐PB, PB‐MC, and MC‐MC
plans. For all seven target volumes of each patient in the current
study, a reduction in EUD (p ≤ 0.001) was noticed when PB opti-
mized plans are calculated using MC. On average, EUD in PB‐MC
plans was reduced by 2.3 Gy(RBE) for CTV_AxI, 1.8 Gy(RBE) for
CTV_AxII, 1.8 Gy(RBE) for CTV_AxIII, 1.9 Gy(RBE) for CTV_CW/
breast, 3.2 Gy(RBE) for CTV_IMN, and 3.1 Gy(RBE) for CTV_SCVN.
The comparison between MC‐MC and PB‐PB plans showed that
EUD was comparable (P > 0.05): 50.7 Gy(RBE) vs. 51.0 Gy(RBE) for
AxI, 50.6 Gy(RBE) vs. 51.0 Gy(RBE) for AxII, 50.4 Gy(RBE) vs.
50.7Gy(RBE) for AxIII, 50.1 Gy(RBE) vs. 50.4 Gy(RBE) for CTV_CW/
breast, 50.1 Gy(RBE) vs. 50.5 Gy(RBE) for CTV_IMN, and 50.2 Gy
(RBE) vs. 50.5 Gy(RBE) for CTV_SCVN. EUD results of CTV_Total
are displayed in Fig. 4. In comparison to PB‐PB plans, EUD of
CTV_Total was comparable in MC‐MC plans (50.4 Gy(RBE) vs.
50.2 Gy(RBE); P = 0.430), whereas PB‐MC plans showed reduction
(P < 0.001) in EUD of CTV_Total by an average difference of 1.9 Gy
(RBE).
3.D | TCP analysis
Table 6 and Figs. 4 and 5 show the TCP results in PB‐PB, PB‐MC, and
MC‐MC plans. The results are averaged over ten breast cancer
patients. In comparison to PB‐PB plans, PB‐MC plans consistently
showed the reduction in TCP by an average difference of 1.9%
F I G . 1 . A sample dose volume
histograms of clinical target volume
(CTV_Total) in PB optimization followed by
PB dose calculation, PB optimization
followed by MC dose calculation, and MC
optimization followed by MC dose
calculation plans of an example patient.
Treatment planning goal: CTV_Total
D95% = 95% of prescription dose (50.4 Gy
relative biological effectiveness (RBE)).
F I G . 2 . Dose distributions in PB optimization followed by PB dose
calculation, PB optimization followed by MC dose calculation, and
MC optimization followed by MC dose calculation plans of an
example patient. Treatment planning goal: clinical target volume
(CTV_Total) D95% = 95% of prescription dose (50.4 Gy relative
biological effectiveness (RBE)).
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(P < 0.001) for CTV_AxI, 1.5% (P = 0.002) for CTV_AxII, 1.7%
(P = 0.001) for CTV_AxIII, 1.7% (P = 0.002) for CTV_CW/breast, 2.8%
(P = 0.003) for CTV_IMN, 2.9% (P < 0.001) for CTV_SCVN, and 1.8%
(P < 0.001) for CTV_Total. In contrast, MC‐MC plans achieved TCP
results similar to the ones in PB‐PB plans. On average, TCP results
were similar in PB‐PB and MC‐MC plans for all CTV structures:
F I G . 3 . Robust evaluation of the D95% of the total clinical target volume (CTV_Total) in PB-PB (PB optimization followed by PB dose
calculation), PB-MC (PB optimization followed by MC dose calculation), and MC-MC (MC optimization followed by MC dose calculation) plans
for ten breast cancer patients. Each plan was evaluated for range uncertainty of ±3.5% and isocenter shifts of X = ±5 mm, Y = ±5 mm, and
Z = ±5 mm. The acceptable robustness criteria for the intensity‐modulated proton therapy breast was 95% of the CTV_Total is covered by at
least 90% of the prescribed dose (i.e., D95% ≥ 45.36 Gy(RBE)).
TAB L E 4 EUD of CTV_AxI, CTV_AxII, and CTV_AxIII in nominal PB‐PB, PB‐MC, and MC‐MC plans of breast cancer.
Patient #
CTV_AxI CTV_AxII CTV_AxIII
EUD (Gy(RBE) EUD (Gy(RBE) EUD (Gy(RBE)
PB‐PB PB‐MC MC‐MC PB‐PB PB‐MC MC‐MC PB‐PB PB‐MC MC‐MC
1 51.7 49.6 51.7 51.6 50.4 51.6 50.9 50.0 50.9
2 51.8 49.9 51.4 51.7 49.8 51.3 51.4 50.0 51.1
3 50.6 48.2 50.5 50.6 48.8 50.5 50.6 49.1 50.5
4 50.5 48.9 49.5 50.5 49.3 49.5 49.9 47.3 49.7
5 51.6 49.2 51.4 51.8 50.3 51.7 51.3 49.5 50.8
6 49.9 47.7 49.8 49.8 47.4 49.8 49.9 47.3 49.7
7 50.8 47.1 50.9 50.8 48.6 50.8 50.8 48.6 50.8
8 51.2 49.0 50.3 51.2 49.4 50.3 51.2 49.6 50.2
9 51.0 49.2 50.2 50.9 49.2 50.0 50.8 49.2 49.8
10 50.8 48.6 50.8 50.7 48.8 50.7 50.7 48.6 50.7
Average 51.0 48.7 50.7 51.0 49.2 50.6 50.7 48.9 50.4
SD 0.6 0.9 0.7 0.6 0.9 0.7 0.5 1.0 0.5
P‐value <0.001 0.271 <0.001 0.272 0.001 0.162
PB‐PB, PB optimization followed by PB dose calculation; PB‐MC, PB optimization followed by MC dose calculation; MC‐MC, MC optimization followed
by MC dose calculation; CTV, clinical target volume, EUD, equivalent uniform dose; RBE, relative biological effectiveness.
aP‐value for PB‐MC vs. PB‐PB.
bP‐value for MC‐MC vs. PB‐PB.
RANA ET AL. | 41
TAB L E 5 EUD of CTV_CW/Breast, CTV_IMN, and CTV_SCVN in nominal PB‐PB, PB‐MC, and MC‐MC plans of breast cancer.
Patient #
CTV_CW/Breast CTV_IMN CTV_SCVN
EUD (Gy(RBE) EUD (Gy(RBE) EUD (Gy(RBE)
PB‐PB PB‐MC MC‐MC PB‐PB PB‐MC MC‐MC PB‐PB PB‐MC MC‐MC
1 50.7 48.9 50.7 51.1 49.1 51.1 51.3 48.1 51.3
2 51.3 49.6 51.0 51.0 48.3 51.0 51.2 48.8 51.7
3 50.4 48.3 50.2 50.2 44.7 49.7 50.2 47.3 50.0
4 49.1 47.1 49.0 49.3 46.1 49.1 49.0 45.8 48.8
5 50.2 48.5 49.2 51.4 47.8 50.7 51.4 48.3 50.8
6 49.1 47.1 49.0 49.3 46.1 49.1 49.0 45.8 48.8
7 50.9 48.4 51.0 52.1 48.9 52.0 51.0 47.1 50.6
8 51.0 49.4 50.1 51.1 48.1 50.3 51.1 48.2 49.9
9 50.7 49.2 49.9 48.9 46.0 47.8 50.7 47.6 49.8
10 50.8 48.7 50.7 50.5 47.5 50.4 50.6 47.2 50.6
Average 50.4 48.5 50.1 50.5 47.3 50.1 50.5 47.4 50.2
SD 0.7 0.9 0.8 1.0 1.5 1.2 0.9 1.0 1.0
P‐value <0.001 0.289 <0.001 0.447 <0.001 0.327
PB‐PB, PB optimization followed by PB dose calculation; PB‐MC, PB optimization followed by MC dose calculation; MC‐MC, MC optimization followed
by MC dose calculation; CTV, clinical target volume; CW, chestwall; EUD, equivalent uniform dose; IMN, internal mammary nodes; SCVN, supraclavicu-
lar nodes; RBE, relative biological effectiveness.
aP‐value for PB‐MC vs. PB‐PB.
bP‐value for MC‐MC vs. PB‐PB.
F I G . 4 . D95%, tumor control probability, and equivalent uniform dose of the total clinical target volume (CTV_Total) for breast cancer
patients (n = 10) in PB-PB (PB optimization followed by PB dose calculation), PB-MC (PB optimization followed by MC dose calculation), and
MC-MC (MC optimization followed by MC dose calculation) plans generated by intensity‐modulated proton therapy (IMPT) technique.
TAB L E 6 Tumor control probability results in nominal PB‐PB, PB‐MC, and MC‐MC plans of breast cancer. The results are averaged over ten
breast cancer patients.
PB‐PBAvg. (±SD) PB‐MCAvg. (±SD) P‐value MC‐MCAvg. (±SD) P‐value
CTV_Total TCP (%) 93.2 (±0.6) 91.4 (±0.7) <0.001 92.9 (±0.6) 0.345
CTV_CW/Breast TCP (%) 92.9 (±0.9) 91.2 (±1.2) 0.002 92.7 (±0.7) 0.535
CTV_AxI TCP (%) 93.4 (±0.5) 91.5 (±1.0) <0.001 93.2 (±0.6) 0.545
CTV_AxII TCP (%) 93.3 (±0.7) 91.8 (±0.9) 0.002 93.1 (±0.7) 0.571
CTV_AxIII TCP (%) 93.4 (±0.5) 91.7 (±0.9) 0.001 93.1 (±0.6) 0.326
CTV_IMN TCP (%) 93.0 (±1.3) 90.2 (±2.1) 0.003 92.9 (±1.4) 0.940
CTV_SCVN TCP (%) 93.4 (±0.7) 90.5 (±1.2) <0.001 93.1 (±0.7) 0.385
PB‐PB, PB optimization followed by PB dose calculation; PB‐MC, PB optimization followed by MC dose calculation; MC‐MC, MC optimization followed
by MC dose calculation; CW, chestwall; EUD, equivalent uniform dose; IMN, internal mammary nodes; SCVN, supraclavicular nodes; TCP, tumor control
probability.
aP‐value for PB‐MC vs. PB‐PB.
bP‐value for MC‐MC vs. PB‐PB.
42 | RANA ET AL.
CTV_AxI (93.4% vs. 93.2%; P = 0.545), CTV_AxII (93.3% vs. 93.1%;
P = 0.571), CTV_AxIII (93.4% vs. 93.1%; P = 0.326), CTV_CW/breast
(92.9% vs. 92.7%; P = 0.535), CTV_IMN (93.0% vs. 92.9%; P = 0.940),
CTV_SCVN (93.4% vs. 93.1%; P = 0.385), and CTV_Total (93.2% vs.
92.9%; P = 0.345). Figure 6 shows the TCP of CTV_Total and in PB‐
PB, PB‐MC, and MC‐MC plans of an example patient.
3.E | NTCP analysis
Table 7 shows the NTCP results for the heart, ipsilateral lung, and
skin. There was no clear distinction among PB‐PB, PB‐MC, and MC‐
MC plans in terms of NTCP results. Based on the LKB model and
published radiobiological parameters used in this study, the NTCPs
were 0% for the heart, ≤0.2% for the skin, and 0.4% to 1.9% for the
ipsilateral (left) lung. Figure 6 shows the NTCP of the heart, left lung,
and skin in PB‐PB, PB‐MC, and MC‐MC plans of an example patient.
3.F | Patient‐specific quality assurance (QA)
analysis
Patient‐specific QA measurement was done for PB‐PB plans of
all ten patients in a water tank using DigiPhant‐PT (IBA Dosime-
try, Schwarzenbruck, Germany) and MatriXX‐PT (IBA Dosimetry,
Schwarzenbruck, Germany). A 2D gamma analysis was per-
formed between the calculated and measured 2D dose distribu-
tions using patient‐specific QA module implemented within
myQA software platform (IBA Dosimetry, Schwarzenbruck, Ger-
many). For 2D gamma evaluation, we utilized 3% and 3 mm cri-
teria and low‐dose threshold of 10%. A gamma passing rate
of ≥ 90% was considered to be an acceptable level. Table 8
shows the gamma evaluation results of all ten patients. The
average 2D gamma was 94.0% ± 2.9% with a minimum of
90.1% and a maximum of 98.9%.
F I G . 5 . Tumor control probability of the total clinical target volumes for breast cancer patients (n = 10) in PB optimization followed by PB
dose calculation, PB optimization followed by MC dose calculation, and MC optimization followed by MC dose calculation plans generated by
intensity‐modulated proton therapy technique.
F I G . 6 . Tumor control probability clinical
target volume (CTV_Total) and normal
tissue complication probability (heart, skin,
and left lung) in PB optimization followed
by PB dose calculation, PB optimization
followed by MC dose calculation, and MC
optimization followed by MC dose
calculation plans of an example patient.
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4 | DISCUSSION
Previous studies on RayStation proton dose calculation algorithms
were mostly focused on the dosimetric impact of algorithms involv-
ing either phantom3–7 or disease sites.5,7,8 To our best knowledge, at
the time of writing this paper, there is currently no literature that
has addressed the radiobiological impact of RayStation PB and MC
in IMPT breast treatment plans. It is essential to investigate how
dosimetric accuracy of dose calculation algorithms can be translated
to the radiobiological differences in clinical patient cases. Hence, the
current study was undertaken to demonstrate the radiobiological
impact of RayStation PB and MC in terms of EUD, TCP, and NTCP
in IMPT breast cancer treatment plans.
For breast cancer treatment, a tumor volume is often situated at
a shallower depth. This necessitates the use of a proton beam with
a smaller range. However, our proton system has a minimum of
4.0 cm range in water. Hence, for the treatment of shallower target
such as in the case of CW/breast, a range shifter is typically used to
reduce the energy of the proton beam. Although the use of range
shifter allows to achieve full dose modulation of the tumor volume
that may be extended close to the skin, an accurate modeling of
algorithms accounting for angular distribution of a pencil proton
TAB L E 7 NTCP of heart, lung, and skin in nominal PB‐PB, PB‐MC, and MC‐MC plans of breast cancer.
Patient #
Heart Skin Ipsilateral Lung
NTCP (%) NTCP (%) NTCP (%)
PB‐PB PB‐MC MC‐MC PB‐PB PB‐MC MC‐MC PB‐PB PB‐MC MC‐MC
1 0.0 0.0 0.0 0.0 0.0 0.0 0.9 1.0 1.0
2 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.8 0.8
3 0.0 0.0 0.0 0.1 0.0 0.1 0.8 0.9 0.9
4 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.7 0.6
5 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.4 0.5
6 0.0 0.0 0.0 0.0 0.0 0.0 1.7 1.9 1.8
7 0.0 0.0 0.0 0.0 0.0 0.0 0.9 1.0 0.9
8 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.8 0.8
9 0.0 0.0 0.0 0.2 0.1 0.1 0.9 1.0 0.8
10 0.0 0.0 0.0 0.1 0.1 0.1 1.5 1.6 1.6
Average 0.0 0.0 0.0 0.0 0.0 0.0 0.9 1.0 1.0
SD 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.4 0.4
P‐value 0.968a 0.968b 0.674a 0.936b 0.384a 0.674b
PB‐PB, PB optimization followed by PB dose calculation; PB‐MC, PB optimization followed by MC dose calculation; MC‐MC, MC optimization followed
by MC dose calculation; NTCP, normal tissue complication probability.
aP‐value for PB‐MC vs. PB‐PB.
bP‐value for MC‐MC vs. PB‐PB.
TAB L E 8 2D gamma evaluation results from patient‐specific QA.
Calculated (PB‐PB plans) and measured 2D dose distributions were
compared using patient‐specific QA module implemented within the
myQA software platform.
Patient #
Gamma passing rate (%)
Field 1 Field 2
1 95.4 92.9
2 90.6 98.9
3 93.5 98.3
4 96.0
5 94.2 98.4
6 91.1 90.1
7 92.5 90.3
8 94.9
9 94.2
10 92.8
PB‐PB, PB optimization followed by PB dose calculation; QA, quality
assurance.
Gamma evaluation criteria = 3% and 3 mm; Low‐dose threshold = 10%;
Accepted gamma passing rate ≥90%.
F I G . 7 . Computation time in minutes for intensity‐modulated
proton therapy breast plans (PB optimization followed by PB dose
calculation and MC optimization followed by MC dose calculation) of
ten breast cancer patients.
44 | RANA ET AL.
beam after traversing the range shifter and translation of angular dis-
tribution into a geometric spread of proton beam’s cross‐section at
the detector/patient surfaces is critical.9,21
It has been reported that recalculation of PB plans using MC will
result in decrease in target dose and coverage. In a breast study by
Tommasino et al.,7 the MC recomputed average dose to the planning
target volume (PTV) was 7.1% lower than the prescription dose of
50 Gy. Liang et al.8 reported the reduction of CTV Dmean by 2.1% of
the prescription dose in MC recomputed plans compared with PB
plans. In the current study, we observed the reduction of the
CTV_Total Dmean in PB‐MC plans by an average difference of 2.7%
(range, 1.6–3.5%) when compared to PB‐PB plans. Liang et al.8 also
reported the reduction of CTV D99% and CTV D95% by 3.7% and
3.4%, respectively, when PB plans are recalculated with MC. The
findings from the current study agree with that of Liang et al.8 such
that we noticed the reduction of the CTV_Total D99% and D95% in
PB‐MC plans by an average difference of 5.3% and 4.1%, respec-
tively, when compared to PB‐PB plans.
RayStation has made MC available for plan optimization. MC‐op-
timized plans offered optimal CTV coverage and dose distribution
similar to the ones in the PB plan. The current study agrees with the
results from the Liang et al.8 such that CTV_Total dose between
MC‐MC and PB‐PB plans was found to be minimal (<0.5% for both
D95% and Dmean; 1.4% for D99%). The differences between Liang
et al.8 and our study may be attributed to the planning techniques.
For instance, Liang et al.8 normalized PB optimized plans and MC
optimized plans such that 95% of the PTV was covered by 95% of
the prescription dose, whereas plan normalization technique was not
utilized in our study.
If MC is more accurate than PB for IMPT treatment of shallower
targets requiring range shifter as reported in the literature,3–7 dosi-
metric results comparing PB‐PB vs. PB‐MC plans in the current study
suggest that PB overestimates the target dose and coverage. Based
on the radiobiological results in the current study, PB slightly overes-
timated the TCP for all CTV structures by 1–3% for AxI, 1–2% for
AxII, 1–3% for AxIII, 1–3% for CW/breast, 2–4% for IMN, 2–4% for
SCVN, and 1–2% for CTV_Total. Similarly, PB overestimated the
EUD of target volumes by 1.8–3.2 Gy(RBE). However, the choice of
optimization and dose calculation algorithms did not produce any
noticeable differences in the NTCP of the heart, lung, and skin. It
has been reported that breast cancer patients treated with proton
therapy could have the risk of acute skin toxicities.22,23 The NTCP
of skin for the clinical endpoint of severe acute toxicity in our study
was ≤0.2% for all ten patients. This was calculated using the LKB
model and radiobiological parameters predicted by Pastore et al.20 It
must be noted that radiobiological evaluation in our study was car-
ried out based on radiobiological parameters that are derived from
the conventional mega‐voltage X‐ray (photon) therapy. This is a limi-
tation of our study. As more breast cancer patients are being treated
using proton therapy and enrolled in clinical trials, there is a need
for proton derived NTCP models correlating to the tissue toxicities
of breast cancer patients. Due to lack of proton derived radiobiologi-
cal parameters, researchers continue to use photon‐derived NTCP
models for proton therapy.12,14,25 Recently, Blanchard et al.24 vali-
dated photon‐derived NTCP models that can be used to select head
and neck patients for proton treatment.
The current study assumed constant RBE value of 1.1. Several
publications26,27 have demonstrated the existence of variable RBE
for proton therapy and depend on the cell type, endpoint, LET, radi-
ation dose, etc. The variability in RBE could lead to different α/β val-
ues, thus impacting EUD, TCP, and NTCP.28 In this study, we did
not explore the impact of variable RBE on IMPT breast plans. Our
future work will investigate how the combination of variable RBE
and proton dose calculation algorithm can affect the radiobiological
results.
One of the challenges associated with MC plan optimization is
the treatment planning efficiency. Figure 7 illustrates the computa-
tion time in minutes for PB‐PB and MC‐MC plans of all ten
patients. For PB‐PB plans, the average computation time was 13.3
± 4.1 min (range, 7–20 min), whereas the average computation time
for MC‐MC plans was 44.4 ± 12.1 min (range, 26–64 min). Overall,
PP‐PB plans had higher computation efficiency, with an average fac-
tor of 3.4 when compared to MC‐MC plans. It must be noted that
IMPT plan optimization time is dependent on several factors such
as computing hardware and software resources, robustness scenar-
ios, number of optimization structures and their constraints, and
optimization settings (number of iterations and sampling history –
number of ions/spot).
5 | CONCLUSION
If RayStation MC is more accurate than PB as reported in the litera-
ture, dosimetric and radiobiological results from the current study
suggest that PB overestimates the target dose, EUD, and TCP for
IMPT breast cancer treatment. The overestimation of dosimetric and
radiobiological results of the target volume by PB needs to be fur-
ther interpreted in terms of clinical outcome. The use of RayStation
MC for both plan optimization and dose calculation of IMPT breast
cancer plans can provide optimal target coverage and radiobiological
results (EUD and TCP for target volumes) with better accuracy.
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